Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Background: Anthracyclines such as doxorubicin remain a primary treatment for hematological malignancies and breast cancers. However, cardiotoxicity induced by anthracyclines, possibly leading to heart failure, severely limits their application. The pathological mechanisms of anthracycline-induced cardiac injury are believed to involve iron-overloa...
Alternative Titles
Full title
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e6a9333adc1b438598e7eee968dccf49
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e6a9333adc1b438598e7eee968dccf49
Other Identifiers
ISSN
2076-3921
E-ISSN
2076-3921
DOI
10.3390/antiox12020320
